The resistance of MDSCs to sunitinib is believed to be associated with granulocyte-macrophage colony-stimulating factor (GM-CSF) in RCC, but sunitinib combined with GM-CSF treatment still led to resistance to sunitinib both in vivo and in vitro (71). The gene discussed is CSF2; the disease is renal cell carcinoma.